This article is more than 5 years old. Information may no longer be current.

No benefit to indocyanine green before TTT, study says

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BRUSSELS, Belgium — Using indocyanine green before transpupillary thermotherapy does not seem to be beneficial in the treatment of choroidal melanoma, according to a study.

Patrick De Potter, MD, PhD, and Jacques Jamart, MD, PhD, here at the Université Catholique de Louvain conducted a prospective, randomized, controlled study of 60 patients with posterior pole choroidal melanoma. Thirty patients were treated by transpupillary thermotherapy (TTT) alone and 30 were treated with indocyanine green (ICG) before TTT. In this group, the timing of TTT was determined using ICG angiography.

During a mean follow-up of 30 months, tumor thickness was decreased by 30% at month 6 in the TTT group and by 31% at month 6 in the TTT with ICG group. Tumor control was achieved in 92%. Two patients developed tumor recurrence in the TTT treatment group and three developed tumor recurrence in the TTT and ICG group.

The researchers said a larger patient sample and longer follow-up periods will be necessary to determine what, if any, role ICG plays in this type of therapy.

The study is published in the February issue of Ophthalmology.